Premium
A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome
Author(s) -
Blaszyk Hagen,
Hartmann Arndt,
Cunningham Julie M.,
Schaid Daniel,
Wold Lester E.,
Kovach John S.,
Sommer Steve S.
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000120)89:1<32::aid-ijc6>3.0.co;2-g
Subject(s) - medicine , breast cancer , oncology , adverse effect , mutation , cancer , retrospective cohort study , gene mutation , prospective cohort study , adjuvant therapy , adjuvant , gene , biology , genetics
Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow‐up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence ( p = 0.0032) and death ( p = 0.0001), and was associated with poor response to both adjuvant ( p = 0.0001) and palliative ( p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. Int. J. Cancer (Pred. Oncol.) 89:32–38, 2000. © 2000 Wiley‐Liss, Inc.